

# Genomic Basis for Methicillin Resistance in *Staphylococcus aureus*

Keiichi Hiramatsu<sup>1,2</sup>, Teruyo Ito<sup>1</sup>, Sae Tsubakishita<sup>3</sup>, Takashi Sasaki<sup>4</sup>, Fumihiko Takeuchi<sup>4</sup>, Yuh Morimoto<sup>1,2</sup>, Yuki Katayama<sup>1</sup>, Miki Matsuo<sup>1</sup>, Kyoko Kuwahara-Arai<sup>1</sup>, Tomomi Hishinuma<sup>1,2</sup>, and Tadashi Baba<sup>1,2</sup>

<sup>1</sup>Department of Bacteriology, and <sup>2</sup>Research Center for Infection Control Science, Juntendo University, Tokyo; <sup>3</sup>Department of Veterinary Science, Rakuno Gakuen University, Hokkaido; <sup>4</sup>National Institute of Infectious Diseases, Tokyo, Japan

Since the discovery of the first strain in 1961 in England, MRSA, the most notorious multidrug-resistant hospital pathogen, has spread all over the world. MRSA repeatedly turned down the challenges by number of chemotherapeutics, the fruits of modern organic chemistry. Now, we are in short of effective therapeutic agents against MRSA prevailing among immuno-compromised patients in the hospital. On top of this, we recently became aware of the rise of diverse clones of MRSA, some of which have increased pathogenic potential compared to the classical hospital-associated MRSA, and the others from veterinary sources. They increased rapidly in the community, and started menacing otherwise healthy individuals by causing unexpected acute infection. This review is intended to provide a whole picture of MRSA based on its genetic makeup as a versatile pathogen and our tenacious colonizer.

**Key Words:** *oriC* environ, *SCCmec*, *mecA*, *mecB*, *mecC*, *rpoB*, Hetero-resistance

## Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) is an *S. aureus* that became resistant to  $\beta$ -lactam antibiotics by acquiring *mecA* gene on its chromosomal DNA [1]. MRSA was first isolated in 1960 in England [2], and became a worldwide epidemic since 1970s. At least three distinct genotypes of MRSA were present in the 1980s [1], and two of them are still prevalent in the world as multi-drug-resistant healthcare-as-

sociated MRSA (HA-MRSA) [3]. They acquired resistance to practically all the antibiotics introduced into clinical use in the past half century. They conquered even the 'last-resort' antibiotic vancomycin [4, 5]. On top of it, from the early 1990s, MRSA with non-multi-drug-resistance phenotype emerged from various countries of the world such as Australia [6, 7], the USA [8], and France [9]. These MRSA strains appeared to have emerged outside the hospital and designated community-associated (or acquired) MRSA (CA-MRSA). The year 2010

**Received:** April 16, 2013

**Corresponding Author :** Keiichi Hiramatsu, MD, PhD

Professor of Bacteriology, Department of Bacteriology and Infection Control Science, Juntendo University, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan


Tel: +81-3-5802-1040, Fax: +81-3-5684-7830

E-mail: [khiram06@juntendo.ac.jp](mailto:khiram06@juntendo.ac.jp)

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyrights © 2013 by The Korean Society of Infectious Diseases | Korean Society for Chemotherapy

[www.icjournal.org](http://www.icjournal.org)




marked the 50th anniversary of our continuous struggle with MRSA. However, with an unexpected new surge of MRSA strains in both hospital and community, we are forced to fight an even bitterer fight with them. In this review, we describe the genetic feature of the organism to lay a basis for our future project to control MRSA.

## *S. aureus* genome

### 1. Genomic islands (GIs)

*S. aureus* possesses several GIs on the chromosome. Figure 1A illustrates comparison of the genome structures of 14 *S. aureus* strains. All open reading frames (*orfs*) identified on their chromosomes are shown as vertical lines, in which 1887 (denoted by grey lines) are commonly shared by the 14 strains. Red lines indicate the *orfs* that are not present in all the strains. On each chromosome there are regions where

grey lines are sparse and red lines predominate. Those regions correspond to GIs. The genes essential for the life of bacteria are all included in the grey *orfs*. In contrast, GIs include genes associated with virulence or useful genes for some specific environmental challenges (e.g. drug-resistance gene), which presumably were acquired from other organisms by horizontal gene transfer. These *S. aureus* GIs include integrated prophages, *oriC* environ (discussed later) and vSa islands (v stands for island) [10]. The *S. aureus* GIs are mostly comprised of exogenous genes acquired by intra-species gene transfer [11]. Since *S. aureus* is by far the most virulent among various staphylococcal species, the GIs contain many virulence genes such as *tsst-1* encoding toxic shock syndrome toxin, and multiple enterotoxin (*se*) genes. There are two classes in the vSa islands: the first class is designated vSan where *n* is an Arabic numeral indicating the position in the *S. aureus* chromosome where it is localized. They correspond to the integration sites for the mobile pathogenicity islands of *Staphylococcus* (SaPI)



**Table 1.** The list of *S. aureus* genomic islands

The class of islands <sup>a</sup>	The name of each island <sup>b</sup>	attachment site sequence (direct repeats [DR])	Strain	location and size of the element <sup>c</sup>			The <i>orf</i> encoding integrase	The <i>orf</i> containing in the attachment site and its encoded function	Reference or accession number
				Start	End	Size			
vSa1	SaPI1	TTATTTAGCAGGAATAA	RN4282	-	-	15254	-	-	[12]
	SaPI3	TTATTTAGCAGGAATAA	COL	903332	919283	15952	ORF0885	ORF0884 ABCtransporter	[19, 105]
	SaPI5	TTATTTAGCAGGAATAA	USA300 FPR3757	881837	895809	13973	ORF0799	ORF0798 ABCtransporter	[76]
	SaPI5	TTATTTAGCAGGAATAA	USA300 TCH1516	895785	909757	13973	ORF0850	ORF0849 ABCtransporter	[106]
vSa2	SaPIbov1	TAATTATTCCCACTCAAT	RF122 (ET3-1)	388732	404639	15908	ORF0342	ORF0341 glutamine-hydrolyzing GMP synthase	[103, 107]
	SaPIbov2	TAATTATTCCCACTCGAT	V329	-	-	26788	-	-	[108]
vSa3	SaPI <sub>m</sub> 4 (SaGI <sub>m</sub> )	TCCCGCCGTCTCCAT	Mu50	868335	882834	14500	ORF0783	SAVTMRNA01 tmRNA	[109]
	SaPI <sub>m</sub> w2	TCCCGCCGTCTCCAT	MW2	839358	853808	14451	ORF0745	MWTMRNA01 tmRNA	[10]
vSa4	SaPI <sub>n</sub> 1	GTTTTACATCAITCCCGGCAT	N315	2056679	2072358	15680	ORF1835	ORF1836 groEL	[109]
	SaPI <sub>m</sub> 1	GTTTTACATCAITCCCGGCAT	Mu50	2133112	2148788	15677	ORF2028	ORF2029 groEL	[109]
	SaPI6 $\Delta$	GTTTTACATCAITCCCGGCAT/ GTTTTACATCAITCCTGGCAT	NCTC8325	2083635	2086777	3143	ORF2252	ORF2254 groEL	NC_007795
	SaPI6 $\Delta$	GTTTTACATCAITCCCGGCAT/ GTTTTACATCAITCCTGGCAT	COL	2072899	2076041	3143	ORF2015	ORF2016 groEL	[19]
	SaPI6 $\Delta$	GTTTTACATCAITCCCGGCAT/ GTTTTACATCAITCCTGGCAT	USA300 FPR3757	2136710	2139851	3142	2139193bp- 2139739bp	ORF1982 groEL	[76]
	SaPI6 $\Delta$	GTTTTACATCAITCCCGGCAT/ GTTTTACATCAITCCTGGCAT	USA300 TCH1516	2137347	2140488	3142	ORF2023	ORF2024 groEL	[106]
	SaPI6 $\Delta$	GTTTTACATCAITCCCGGCAT/ GTTTTACATCAITCCTGGCAT	MSSA476	2077051	2080192	3142	ORF1934	ORF1935 groEL	[74]
	SaPI6 $\Delta$	GTTTTACATCAITCCCGGCAT/ GTTTTACATCAITCCTGGCAT	MW2	2097809	2100950	3142	ORF1951	ORF1953 groEL	[10]
	SaPI6 $\Delta$	GTTTTACATCAITCCCGGCAT/ GTTTTACATCAITCCTGGCAT	Newman	2141282	2144424	3143	ORF1936	ORF1937 groEL	[110]
	SaPI122 (SaPIbov3)	GTTTTACATCAITCCTGGCAT/ TTTTTACATCAITCCTGGCAT	RF122 (ET3-1)	2021991	2038438	16448	ORF1912	ORF1913 groEL	[103]
	SaPI2 (SaRifusB) <sup>d</sup>	ATTTTACATCAITCCTGGCAT TTTTTACATCAITCCTGGCAT	RN3984 CS6 (EEFIC) <sup>e</sup>	- -	- -	14755 20744	- -	- groEL	[111] [14]
	vSa5	SaPI4	AAAGAAGAACAATAATAT	MRSA252	409098	424214	15117	ORF0365	ORF0364 rpsR
SaPI1028 ( $\phi$ PT1028)		AAAGAAGAACAATAATAT	NY940	-	-	15603	-	-	[112]

<sup>a</sup>Classified based on the integration site on the *S. aureus* chromosome. Correlated with the integrase phylogeny (see Figure 1B).

<sup>b</sup>The name for the individual mobile element proposed by R. Novick [13].  $\Delta$  signifies that the element is a remnant. The name in parenthesis is the one originally described.

<sup>c</sup>Start, the first nucleotide position of the left direct repeat (DR); End, the last nucleotide of the right DR; Size, in base pairs (bp); -, unknown because whole genome sequence data is unavailable.

<sup>d</sup>*S. aureus* resistance island carrying *fusB* [14].

<sup>e</sup>European fusidic acid-resistant impetigo clone.


and a mobile resistant island (SaRI) [12-14]. The latter nomenclature is based on the unique genetic structure common to these mobile genetic elements. Correlation of the two nomenclature systems is summarized in Table 1. As shown in Figure 1A, vSan classification refers to the location of the attachment site of the islands, and is correlated well with the evolutionary tree for the SaPI integrase gene (Fig. 1B).

The SaPI elements evolved themselves to take advantage of the bacteriophage as the vehicle for efficient intercellular transmission. A representative island, SaPII, carrying *tsst-1*, possesses a packaging system for phage-mediated intercellular transfer [15]. Another island, SaPIbov1, is demonstrated to be carried by a small-sized bacteriophage head that infects *S. aureus* cell and transfer the island into one of the several attachment sites in the chromosome [16, 17]. SaRI has essentially the same structure with SaPI, but it carries a resistance gene to fusidic acid instead of virulence gene [14].

Another class of vSa islands is found on the *S. aureus* chro-

mosome. They carry many virulence-related genes, but do not have apparent device for movements. Curiously, however, a remnant of a transposase gene whose putative intact form is found in the genome of *Macrococcus caseolyticus*, a bacterial species sharing a common ancestor with staphylococcal species [18]. The islands vSaa, vSaβ, vSay, vSaδ, vSae belong to this class of islands [10, 19], where vSaa contains a series of *ssl* (staphylococcal superantigen-like) genes [20, 21]; vSaδ, (previously designated vSay [22, 23], carries genes encoding exfoliative toxin D (ETD) and epidermal cell differentiation inhibitor (EDIN); and vSae carries accessory gene regulators T and U involved in the virulence regulation [24], and gene clusters encoding putative lipoproteins and fibronectin-binding proteins.

Figure 2 illustrates chromosomal localization of the *orfs* conserved across four staphylococcal species *S. aureus*, *S. epidermidis*, *S. haemolyticus* and *S. saprophyticus*. It shows that the order of the conserved *orfs* (synteny) is much more re-



**Figure 2.** Orthologous *orfs* commonly shared by 17 staphylococcal strains of four species. After identifying common orthologs among various species, conserved chromosomal structure ("core structure") was constructed on the basis of the consensus arrangement of the conserved orthologs [104]. An ortholog group in the resulting core structure is indicated as a colored line across horizontal black line representing a chromosome. To simplify the figure, only universally conserved, one-to-one correspondence ortholog groups are shown. To visualize chromosomal rearrangement of the core structure, color gradation is assigned according to the location on *S. aureus* strain N315 chromosome from red to yellow to green. The replication origins (*oriC*) are located at the center. Strain-specific *orfs* are denoted on each chromosome by grey short vertical bars. Note that the species-specific *orfs* are localized in the chromosome region with sparse vertical lines.



tained among *S. aureus* strains as compared to that between the two *S. epidermidis* strains. This coincides with our overall impression that *S. aureus* has a rather conserved (or rigid) chromosome structure when compared with the other two staphylococcal species, *S. epidermidis* and *S. haemolyticus*. The chromosomes of the latter seem to be extremely labile [25, 26].

The region around the origin of replication (*oriC*: located at the center in the illustration) is noted to be sparse for conserved *orfs* across staphylococcal species. This indicates that the region consists of a high proportion of species-specific genes acquired during the evolution of each species. The diversity of the chromosome is more pronounced in the region to the right of *oriC* (*oriC* to +0.5 Mb) than that to the left of *oriC* (-0.3 Mb to *oriC*). This coincides with the presence of *orfX* to the right of *oriC*, which serves as an attachment site for staphylococcal cassette chromosome (SCC), a unique horizontal gene transfer vehicle of staphylococci (discussed later). The figure also shows that the region contain a number of *orfs* unique to each *S. aureus* strain (denoted by grey short vertical bars in Figure 2) presumably acquired by SCC-mediated gene transfer. We designated this region 'oriC environ' [11]. The genetic information accumulated in *oriC* environ would be used by the cell to produce a more fit strain to the niche of survival.

## 2. Mobile genetic elements

*S. aureus* genome contains several copies of insertion sequences (ISs) and transposons (Tns). However, the number of copies is limited, and many of them are inactive suffering from mutations or deletions [18]. In contrast, as many as 82 IS elements are found on the *S. haemolyticus* genome, and most of them are intact [11]. It is curious why the number of IS or Tn are significantly different across staphylococcal species. It is well known that IS turns off a gene function by disrupting it or by inserting itself to the proximity of the target gene (polar effect) [27]. It can also up-regulate a gene transcription by integrating itself to the upstream region of a gene and providing it with a strong promoter activity [28]. In a sense, keeping many intact copies of IS and/or transposons on a chromosome is to keep the chromosome 'soft'. It is advantageous for the survival of such species of bacteria that are frequently exposed to challenging environmental conditions. The genome plasticity of *S. haemolyticus* is reflected in our rather frequent encounter with difficult-to-speciate clinical *S. haemolyticus* strains with their abnormal biochemical features compared to the standard *S. haemolyticus* strain [11]. Extremely high genome plasticity of *S. haemolyticus* might have made the species the first

one to acquire vancomycin resistance [29]. It is also demonstrated that IS256 is more frequently found in nosocomial methicillin-resistant *S. epidermidis* (MRSE) isolates associated with septicemia and urinary tract infections as compared to commensal *S. epidermidis* isolates from healthy volunteers [30]. Consistent with this observation is that an oxacillin-susceptible *S. epidermidis* type strain ATCC12228 does not possess IS256 on the chromosome, whereas MRSE strain RP62A possesses 5 copies of IS256. Historically *S. epidermidis* was next only to *S. haemolyticus* to acquire intermediate vancomycin resistance [29]. Aside from spontaneous mutation as will be described below, IS256-mediated genome alteration might also contribute to the acquisition of vancomycin resistance in the two staphylococcal species.

In contrast to the human pathogenic staphylococci, a non-pathogenic staphylococcal species *S. carnosus* does not have any insertion sequences [31]. The species is isolated from meat products, and has been used safely since the 1950s as a starter culture for the fermentation of dry sausage. In the well-controlled nutrient-rich culture condition, the species would not need to alter the genome composition. So, it is reasonable that it does not maintain mobile genetic elements in the chromosome [31].

## 3. The *oriC* environ

As described above, the *oriC* environ is a region around the *oriC* where multiple exogenous genes are accumulated as a result of repeated horizontal gene transfer events. It contains a number of DNA fragments of various sizes, flanked by characteristic direct repeats (DRs). They are designated staphylococcal cassette chromosomes (SCCs) [32, 33], and are integrated in tandem in the downstream region of *orfX*. The DR contains integration site sequence (ISS) for SCC, which is recognized by cassette chromosome recombinase (CCR). CCR mediates integration into and precise excision of SCC from chromosome [33]. The *orfX* is an *orf* of unknown function located near *oriC* but well conserved among diverse gram-positive bacteria. SCC carries various exogenous genes that are considered to confer certain growth or survival advantages to the host cell. As we saw in Figure 2, the *oriC* environ contains many species-, and strain-specific genes. It is probable that successive integration of SCC formed the *oriC* environ equipped with useful genes to adapt to an unfriendly environment, and thereby contributed to the evolution of new staphylococcal strains or species.

However, the *oriC* environ is not a mere storehouse of foreign genes. It has another function as an extremely active di-

versifier of chromosome. The *oriC* environ serves as the generator of diversity by accumulating foreign genes, deleting useless or hazardous ones, and event inverting large chromosomal fragments across the *oriC*. This process is achieved by the chromosome shuffling mediated by IS and Tn copies abundantly found in *oriC* environ [26].


## Methicillin resistance

### 1. Historical accounts

Search for the genetic determinant of methicillin resistance (*mec*) has a long history. In 1975, Sjöström et al. demonstrated localization of *mec* on the MRSA chromosome [34]. In 1978 Kuhl et al. mapped *mec* in the linkage group II *pyr-his-nov-pur* of MRSA chromosome [35]. In 1980, Stewart and Rosenblum demonstrated that *mec* is localized on a chromosomal region (designated 'additional DNA') of MRSA, which is absent from MSSA chromosome [36]. In the early 1980s, using the penicillin-binding assay of PBP researchers noticed that a novel low-affinity penicillin-binding protein designated PBP2' or PBP2a (MecA) is produced by MRSA [37-40]. The gene *mecA* encoding MecA was subsequently cloned by Matsuhashi et al. by using a physically-linked tobramycin resistance determinant as a marker for cloning [41].

Matsuhashi et al. observed that *mecA* gene was linked to the nucleotide sequence similar to the promoter and truncated homolog of the regulator gene *blaR1* of beta-lactamase (*bla*)-gene complex. The intact *bla*-gene complex has the structure *blaI-blaR1-(p)-blaZ*, where *p* stands for the divergent promoters for *blaZ* and *blaR1*. Since *mecA* was found in the structure  $\Delta blaR1-(p)-mecA$ , they proposed the idea that *mec*-gene complex was produced by recombination event between *mecA* gene and *bla*-gene complex, by homologous recombination [42]. The *blaI* and *blaR1* genes encode repressor and membrane-bound signal transducer, respectively, of *blaZ* transcription. Therefore, it was predictable that the integrated *mecA* gene in the place of *blaZ* was under regulatory control of the *bla* regulator genes. However, the strain which Matsuhashi used for molecular cloning did not contain an intact set of regulator genes. Tesch et al. was the first demonstrating the presence of the region (called *mecR* locus) upstream of *mecA* of methicillin-resistant *S. epidermidis* strain WT55 that strongly repressed expression of MecA [43].

There were methicillin-resistant strains with and without the *mecR* locus [44, 45]. Those having the *mecR* locus tend to be slow in the induced production of MecA by exposure to meth-



**Figure 3.** (A) Basic structure of *SCCmec*. *SCCmec* is bracketed by direct repeats (DRs) that contain integration site sequence (ISS) recognized by cassette chromosome recombinase (CCR). A pair of inverted repeats (IRs) are present at the termini of *SCCmec*. Two critical gene complexes, *ccr* and *mec* are present, and the other regions are designated J1, J2, and J3. The type of *SCCmec* is defined by the combination of the type of *ccr*-gene complex and the class of *mec*-gene complex. Subtype of the *SCCmec* is based on the difference in the J (standing for junkyard) regions. (B) Various types of *SCCmec*. The structures of 11 types of *SCCmec* are illustrated based on the nucleotide sequences deposited in the DDBJ/EMBL/GenBank databases as follows: type I, NCTC10442 (AB033763); type II, N315 (D86934); type III, 85/2082 (AB037671); type IV, CA05 (AB063172); type V, WIS [WBG8318] (AB121219); type VI, HDE288 (AF411935); type VII, JCSC6082 (AB373032); type VIII, C10682 (FJ390057); type IX, JCSC6943 (AB505628); type X, JCSC6945 (AB505630), and type XI, LGA251 (FR821779.1) Direct repeats that comprise integration site sequences of SCC are located at both extremities of *SCCmec* (the red arrowheads). The location of five (A-E) classes of *mec*-gene complexes is indicated by pink belt. The locations of *ccr*-gene complexes are indicated by blue belt. Insertion sequences and transposons are indicated in yellow. Representative genes related to heavy metal resistance and integrated plasmids located in the J regions are also indicated. Type XI is a newly identified *SCCmec* found in the MRSA strains of bovine sources.

icillin [46]. We also identified the *mecR* locus in *S. aureus* strain N315 that was curiously methicillin-susceptible irrespective of the presence of *mecA* gene. The *mecI-mecR1* regulator genes homologous to *blaI-blaR1* were found in the *mecR* locus of N315 [47]. Inactivation of *mecI* gene de-repressed production of MecA, and induced expression of methicillin resistance [48]. The *mecA* gene transcription is also repressed by *bla*-gene complex on a plasmid harbored by N315, but the *bla* regulators allowed much quicker induction of *mecA* on exposure to methicillin. As expected, *mecI* gene was either deleted or mutated in most of the clinical MRSA isolates having apparent methicillin-resistant phenotype [1]. There were also some strains with intact *mecI* gene but having a mutation in the operator region of *mecA* gene to which MecI repressor protein is supposed to bind [1]. The *mecA*-carrying methicillin-susceptible strains as N315 are rarely found in clinical samples. It is consistent with the observation that N315 generates *mecI*-inactivated mutants at high frequencies upon beta-lactam selection in vitro. Such strain as N315 having depressed MecA expression due to the intact *mecI* was considered as a precursor of MRSA, designated pre-MRSA [1, 48].

## 2. SCCmec as a vehicle of methicillin resistance determinant

Using three epidemiologically representative MRSA strains with different genetic backgrounds, we determined the nucleotide sequence of entire additional DNAs [1, 49]. They appeared as long (32->60 Kb) stretches of chromosomal DNA regions with many *orfs* of unknown function within which two important clusters of genes were identified; *mec*-gene complex (encoding methicillin resistance) and cassette chromosome recombinase (*ccr*) -gene complex (encoding one or two site-specific recombinases for the movement of the element) [50] (Fig. 3A). These long DNA regions were found integrated site-specifically at the integration site sequence (ISS) present at the 3' end of *orfX* as if it were a 'cassette' DNA. We designated the element staphylococcal cassette chromosome *mec* (SCCmec) [33]. However, unlike the refined image of the 'cassette' for integrin [51], SCCmec elements were much larger and studded with apparently useless pseudogenes or truncated copies of transposons and insertion sequences. This is the reason why the authors called the regions around the two essential gene clusters as J (standing for 'junkyard') regions [52]. Now, the J region is spelt out as 'joining' and its sequence is used for the subtyping of various SCCmec types [53, 54].

As illustrated in Figure 3A, SCCmec is demarcated by specif-

ic inverted repeats (IR) and direct repeats (DR) that contain integration site sequence acted on by cassette chromosome recombinase (CCR). The element carries the *mecA* gene, as a component of *mec*-gene complex, and *ccr* gene(s) (*ccrAB* or *ccrC*) that encode CCR(s). The integration site for the cassette chromosome is present at the 3'-end of an open reading frame, *orfX*. As a result of integration, the SCC element is flanked by a couple of direct repeat (DR) sequences, both of which serve as integration sites for the next SCC element (Fig. 3A). The function of *orfX* is unknown, but it may encode an important protein. Upon integration of SCCmec, 15 bp of the 3'-end of *orfX* are replaced by the terminal nucleotide sequence of the integrated SCCmec. Curiously, however, in spite of the difference in the nucleotide sequence, the encoded peptide is unchanged before and after the integration of any type of SCCmec [49, 55, 56].


Many types of SCCmec have been found (Fig. 3B). At present, 11 types are registered [57], and more numbers are expected to be found in the future. The SCCmec type is defined by the combination of the type of *ccr*-gene complex and the class of *mec*-gene complex. Types I-III are older SCCmec types that are harbored by HA-MRSA [49]. They are relatively big in size and carry multiple antibiotic resistance determinants. Types IV and V were recognized as new versions of SCCmec that were almost diagnostically harbored by CA-MRSA [55, 56, 58]. They are short, and typically carrying no antibiotic resistance genes other than *mec*-gene complex. These new types of SCCmec are widely distributed among methicillin-resistant non-*aureus* staphylococci (MRNAS) especially among methicillin-resistant *S. epidermidis* (MRSE) carried by Japanese healthy children in the community [25, 59]. Recent study performed in other countries showed wide distribution of type-IV SCCmec among MRSE and type-V SCCmec in methicillin-resistant *S. haemolyticus* (MRSH) in the community [60]. These data indicate that MRNAS serves as the reservoir for horizontal gene transfer of new types of SCCmec to *S. aureus*.

## 3. New types of SCCmec: cost of resistance and influence on virulence

Integration of SCCmec into the *oriC* environ of MSSA chromosome generates MRSA. Therefore, each clone of MRSA (clonotype) can be described by the combination of the genotype of recipient MSSA strain and the genotype of the integrated SCCmec [3, 50, 61]. Recent worldwide outbreak of community-acquired MRSA (CA-MRSA) is caused by the emergence of new molecular types of SCCmec [58]. MRSA carrying new types of SCCmec (types IV and V) appeared in

the last decade and almost simultaneously from various countries in the world [55,56]. As shown in Figure 3B, types IV and V are discriminated from the previously dominant three types of SCCmec (mostly carried by HA-MRSA) with different combinations of *mec*-gene complex and *ccr*-gene complex. When compared with HA-MRSA strains with type I-III SCCmec, CA-MRSA strains carrying type-IV and type-V SCCmec tend to be faster in growth, more virulent, resistant to fewer antibiotic classes (non-multi-resistant), and lower in the degree of beta-lactam resistance (heterogeneously methicillin resistant) [58]. These features of CA-MRSA strains seem to be associated with the structural feature of the new types of SCCmec. The most evident first feature is the small size of the type-IV and -V SCCmec: they carry less number of exogenous genes that might disturb physiology of the cell, and no antibiotic resistance gene against various antibiotic classes besides *mecA* gene [58]. The smaller size of the elements might have helped them distribute in such an explosive way to community *S. aureus* strains by efficient horizontal gene transfer presumably via bacteriophages [62].

Another feature is observed with type-IVa SCCmec, which is widely disseminated in CA-MRSA [58]. All the eight type-IVa SCCmec elements so far sequenced share a mutation in the Shine-Dalgarno (S-D) sequences for *mecA* gene (they have -AGGAGT- instead of -AGGAGG-). This might explain the low phenotypic expression of methicillin resistance (or heteromethicillin resistance) with oxacillin MIC values of 4-64 mg/L of the CA-MRSA strains carrying the type of SCCmec [58]. In most of the MRSA strains, the production of MecA encoded by *mecA* gene is repressed by BlaI repressor protein encoded by *blaI* gene on the penicillinase plasmid [63]. De-repressed expression of the exogenously acquired cell-wall synthesis enzyme MecA seems to cause disadvantage to the cell presumably by disturbing otherwise well organized cell-wall synthesis performed by multiple intrinsic enzymes. In fact, removal of penicillinase plasmid de-represses *mecA* gene expression and causes frequent loss of *mecA* gene during drug-free passage [64, 65]. Lee et al. also examined the cost of acquisition of SCCmec using an MSSA strain NCTC8325 (BB255) [66]. The doubling time of the MSSA strain was 39.3 min. The doubling time of the transformant with type-I SCCmec increased significantly to 54.5 min, whereas that with the type-IV SCCmec was 41.3 min. Moreover, type-IV SCCmec did not impose an energetic cost to its recipient MSSA with regard to the amount of the cell mass produced by consuming a unit of ATP. On the other hand, the presence of type-I SCCmec significantly reduced the cell yield [66]. Type-I SCCmec appears to have a negative ef-



**Figure 4.** The *mecA* gene originated from *Staphylococcus fleurettii* genome. Practically identical *mecA* gene and its surrounding region of SCCmec were identified on the chromosomes of *S. fleurettii*, a member of the *sciuri* group of staphylococcal species. The *mecA*-gene orthologs found in other staphylococcal species at the corresponding chromosomal loci (*mvaS*, a vital gene for life, serves as a landmark for the locus) are either deleted or degenerated presumably due to disuse of their function. Two mobile elements IS431 and Tn554 seem to have excised this part of the chromosome and inserted it into an SCC to form the historically first SCCmec element.

fect on the growth rate and the effective cell reproduction compared to type-IV SCCmec in batch culture. The reason for this difference is yet to be examined, however, Lee et al. referred to the possible contribution of the mutated S-D sequence for *mecA* gene in the type-IV SCCmec used for the experiments [66]. Low expression of MecA due to the mutated S-D sequence may make the cell more fit in the survival in the community where exposure to beta-lactam antibiotics is less frequent than in the hospital.

The third intriguing feature of new SCCmec is the absence of *psm-mec* gene encoding phenol-soluble modulins [67]. It is present adjacent to the *mecI* gene of class-A *mec*-gene complex (Fig. 4). Although *S. aureus* is non-flagellated and unable to move, but some strains as MSSA strain Newman tend to spread on soft agar forming diffuse colonies [68]. Introduction of the *psm-mec* found in class-A *mec* gene complex into Newman suppressed its spreading ability and decreased exotoxin production. Introduction of *psm-mec* also attenuated the virulence of Newman in a murine systemic infection model [69]. Presence of *psm-mec* decreases the production of cytolysin PSM $\alpha$ . PSM $\alpha$  is another phenol-soluble modulin that augments cytokilling activity of Pantone-Valentine leukocidin [70]. Both the transcription and translation products of the *psm-mec* suppressed colony-spreading activity and promoted bio-film formation [71]. This *psm-mec* RNA was found to bind *agr* mRNA and inhibit translation of the *agrA* gene [72]. Since *agrA* encodes a positive transcription factor for the *psmA* gene, the production of PSM $\alpha$  is depressed. The gene is found immediate downstream of *mecI* gene of type-II, type-III, and



type-VIII SCC*mec* elements, whereas it is absent from type-IV and V SCC*mec* elements [69]. The absence of the gene from the new types of SCC*mec* explain at least partially the higher virulence of CA-MRSA strains as compared to HA-MRSA.

#### 4. SCC as a vehicle for genes other than *mecA*

When SCC*mec* was found, it was considered that it is an exclusive vehicle for *mec*-gene complex and some other drug-resistance genes (Fig. 3B). Subsequently, however, SCCs harboring other functional genes than *mecA* started to be found in the *oriC* environ. They carried type-1 capsule gene cluster (SCC*cap1*) [73], fusidic acid resistance gene (SCC*fur*) [74], and mercury resistance operon (SCC*Hg*) [53], penicillin-binding protein 4 [75], and enterotoxin H (*seh*) [10]. Recently, an SCC-like element carrying an arginine deiminase pathway and an oligopeptide permease system (designated arginine catabolic mobile element [ACME]) was found next to a type-IV SCC*mec* element in a CA-MRSA strain prevailing in the USA (designated USA300) [76]. The element is considered to confer better survival ability and increased virulence to the strain. With these observations, now it seems likely that SCC serves as a vehicle for not only drug resistance genes but also diverse genes useful for better adaptation to the unfriendly environment. Multiple SCC elements can be integrated sequentially into one of the DRs bracketing the previously integrated SCC elements. Thereby, accumulation of multiple SCC elements carrying various functions is achieved to allow diversification of *S. aureus* genome.


#### 5. Origin of *mecA* gene

Search for the origin of *mecA* gene was an important project for the researchers of MRSA. First, a *mecA* gene homolog encoding a PBP with 88% amino acid similarity to MecA was found on the chromosome of *S. sciuri* strains [77]. Then a *mecA* gene homolog with practically identical nucleotide sequence (greater than 99%) with *mecA* was discovered on the chromosome of *S. fleurettii* [78], one of the oldest staphylococcal species. As shown in Figure 4, the chromosomal locus containing the complete *mecA*-gene complex as well as the surrounding J regions bracketed by two mobile genetic elements Tn554 and IS431 of type-II SCC*mec* was found in *S. fleurettii* strain SFMP07 [78]. Subsequent whole genome sequencing of the strain revealed that the region was about 240-Kb apart from the *orfX*, and there were multiple SCCs in the vicinity of *orfX* but no copy of it found around the *mecA* gene complex (Tsubakishita et al. in preparation). This indicated that *mecA* was an intrinsic component of the chromosome of *S. fleuret-*

*tii*. It must have been an important PBP for the ancestral staphylococci to survive the environment soaked with  $\beta$ -lactam antibiotics produced by fungi and *Actinobacteria*. The *mecA* gene must have been transmitted vertically during the initial steps of staphylococcal speciation. However, after a while, it became decayed (with mutations) or deleted out from the chromosomes of the descendants as exemplified by the emergence of methicillin-susceptible *S. aureus* (MSSA) as a human colonizer. It is curious why *mecA* gene was lost from the staphylococcal chromosome during speciation. The divergence time of *S. sciuri* group from the major staphylococcal clade including *S. aureus* is calculated to be 200-300 million years ago [79], which corresponds to the geological age of the emergence of mammalian animals. Since then, staphylococcal species evolved with mammals as the colonizers of diverse mammalian animals [79]. Our hypothesis is that the descendants of staphylococci became methicillin-susceptible, because they became protected from the threat of  $\beta$ -lactam-producing fungi or actinobacteria by the immune system of mammalian hosts [79].

#### 6. *mecB* and *mecC*, new *mecA* gene homologs

SCC is a mobile genetic element found only in staphylococcal species and in macrococcal species that are close relatives of the former. The two genera share the same ancestor and diverged from each other about 300 million years ago as inferred by the phylogenetic tree with 16S and 23S DNA sequences and calculation based on the ecological distribution study of staphylococci across mammalian animals [79]. Ge-




**Figure 5.** Novel *mecA* gene homologs *mecB* and *mecC*.

*mecB* (formerly *mecAm*) and *mecC*, are found linked with *blaZ* homolog encoding beta-lactamase. *mecB*-gene complex is associated with transposase genes and transmitted as transposon Tn6045. *mecA*- and *mecC*-gene complexes are transmitted as SCC*mec* elements.

netic study on several  $\beta$ -lactam-resistant *Macrocooccus caseolyticus* strains isolated from China, Japan, and Thailand, revealed that they did not harbor *mecA*. Instead, a novel PBP designated *mecB* was identified on a plasmid, which turned out to be a distantly related *mecA*-gene homolog, and was shown to confer methicillin resistance on the cell. The gene had 61.7% of nucleotide identity with *mecA* (Fig. 5). The *mecB* was also accompanied by regulator genes *mecR1b* and *mecIb* that were also distantly related to the *mecR1a* (53.5% identity) and *mecIa* (60.2% identity), respectively, of the *mecA*-gene complex. Curiously, however, unlike *mecA* gene, *mecB* was accompanied by a *blaZ* homolog (*blaZb*) encoding a putative beta-lactamase. Moreover, unlike *mecA*-gene complex, the *mecB*-gene complex (*blaZb-mecB-mecR1b-mecIb*) was adjoined to transposase genes, forming transposon Tn6045 (Fig. 5). The *mecB* transposon was found on either plasmid (Fig. 6) or chromosome of macrococcal strains. One strain JCSC7096 harbored the transposon on the chromosome next to *orfX*,

and an SCC element carrying *ccrAB* genes was found right next to the transposon [80]. Only one copy of the direct repeats of the transposon separated the two elements, Tn6045 and the SCC. A mere mutational inactivation of transposase or deletion of the direct repeat would be enough to combine the two elements into a new SCC*mec* [80]. The new SCC*mec* may come into the strains of staphylococci in near future, or might have already been there to be found by the researchers.

Recently, another *mecA*-gene homolog designated *mecC* was found on the chromosome of MRSA strains of animal as well as human sources [81, 82]. *mecC* was almost equally distant from *mecA* and *mecB*, and shared the characteristic gene order of *blaZc-mecC-mecR1c-mecIc*, having a *blaZ*-gene homolog next to *mecC* (Fig. 5). However, unlike *mecB*-gene complex, the *mecC*-gene complex was not associated with transposase genes. Instead, it was linked to *ccr*-gene complex forming a novel SCC*mec* (type XI; see Figure 3B). So far, *mecC* has also been found on the chromosome of *S. xylosus* [83], but




**Figure 6.** *mecB* transposon Tn6045 is carried by a big R plasmid.

Physical map of the *Macrocooccus caseolyticus* plasmid pMCCL2 is illustrated [18]. BlastP analysis was performed on the protein product of each *orf*. The bacterial genus of the top-hit entry for each *orf* is denoted by coloration. Those having no entry with e-value of  $1 \times 10^{-6}$  or above, the *orfs* are colored in grey. The plasmid contains antibiotic resistance genes such as *erm* and *aac/aph* genes besides *mecB* transposon. Note that the plasmid contains *orfs* whose top-hit entry converts as many as 13 different genera.

*mecB* has yet to be found in staphylococcal species. A possible explanation for this difference might be due to the host specificity of the mobile genetic elements that carry them; *mecA* and *mecC* are carried by SCC, and *mecB*, by transposon. However, the plasmid carrying the *mecB* transposon seems to have a broad host range (Fig. 6). It is a resistance (R) plasmid carrying genes with diverse blast top-hit entries across several other bacterial genera besides *Macrococcus* and *Staphylococcus*. They cover more than 10 genera including *Enterococcus*, *Bacillus*, and *Streptococcus* (Fig. 6). It is speculated that *mecB* is provided to diverse bacterial genera via the plasmid. And yet, *mecB* has not been found in staphylococcal species. SCC may be a more efficient genetic transfer machinery than plasmid or transposon across staphylococcal species, although we do not know its inter-species transfer mechanism. It would be an important project to look for the vehicle of SCC transmission to reveal seemingly an efficient genetic information exchange system of staphylococcal species.

## 7. Mec superfamily

Figure 7 shows the evolutionary tree of penicillin-binding proteins (PBPs) of *Staphylococcus* species. *S. aureus* has four PBPs, and MRSA has *MecA* or *MecC* acquired by horizontal transfer as the fifth PBP. When the *Macrococcus* *MecB* was used for the homology search, other genera such as *Enterococcus* species were found to have *mec* gene homologs. The *pbp* homologs possessed by *Macrococcus caseolyticus* came between those of the enterococci and staphylococci in terms of the degree of homology. The *MecA* homologs with 83-90% amino acid (aa) identities were found in non-*aureus* staphylococcal species [77, 84]. With the discovery of the *Macrococcus* *MecB* having 52% aa identity to *MecA*, all the *Mec* homologs including recently identified *MecC* were grouped as members of the *Mec* superfamily together with a group of enterococcal PBPs (Fig. 7). This is a significant observation, because it has long been known that enterococcal species especially *E. faecium* is naturally resistant to beta-lactam antibiotics [85]. The degree of resistance as evaluated by beta-lactam MIC was well




**Figure 7.** Phylogenetic tree of Penicillin-Binding Protein (PBP) genes homologous to the *Macrocooccus caseolyticus* PBP genes.

*M. caseolyticus* carries four PBP genes, *pbpA-D* on the chromosome and *mecB* on the plasmid pMCCL2. BlastX was performed with each of the five PBP genes as query. The genes with lower than 55% similarity or 50% query coverage to each of the PBP genes of *M. caseolyticus* were declined for subsequent analysis. All the used nucleotide sequences were obtained from GenBank database (<http://www.ncbi.nlm.nih.gov/Genbank/>). The phylogenetic tree was generated using the neighbor joining method in the ClustalW program (<http://clustalw.ddbj.nig.ac.jp/top-j.html>). The tree was visualized in the Phylodendron Web Form (<http://iubio.bio.indiana.edu/treeapp/treeprint-form.html>). To simplify the tree, we adopted the *pbp* homologs of strain N315 as the representatives of *S. aureus* *pbps*, all the *pbp* homologs of non-*aureus* staphylococcal species, and the most homologous *pbp* from each of the non-staphylococcal bacterial families. *Macrocooccus* genes are depicted in red. Note that *pbp1-3* genes of various gram-positive bacteria are ordered in a similar phylogenetic relationship, whereas the entry of bacterial families or species carrying *mecA* and *pbp4* homologs and their relative phylogenetic distance are significantly different from the former. This indicates that *mecA* and *pbp4* are laterally transmissible genes.

correlated with the degree of binding saturation of PBPs produced by enterococcal strains [86]. Thus the binding affinity of the PBPs and the amount of their production are considered to determine the level of susceptibility of the strain towards beta-lactam antibiotics. PBP5 of *E. faecium* was shown to have the lowest binding affinity to beta-lactam antibiotics. Similarity between MecA and enterococcal low-affinity PBPs was pointed out when *mecA* gene was cloned and sequenced [87]. By the way, a *pbp* gene was found on a plasmid harbored by a beta-lactam resistant *Enterococcus hirae* strain. The predicted protein encoded by the gene, designated PBP3r, had 99.7% amino acid identity to PBP5 of *E. faecium* [88]. Therefore, it seems likely that not only MecB but also other  $\beta$ -lactam-insensitive *pbp* genes were valuable trade articles among bacterial species annoyed by  $\beta$ -lactam-producing fungi or actinobacteria.

### 8. PBP4 as another mobile PBP

Figure 7 also reveals a curious fact that PBP4 is classified into two subgroups based on the Blast homology analysis. One group is named PBP4a that contains *S. aureus* PBP4, and



**Figure 8.** Relative position of *pbp* gene homologs on the chromosome of staphylococcal species.

The figure shows relative location of the *pbp* genes on each chromosome. The arrow on the chromosome denotes the *pbp* gene and its direction of transcription. The relative placement of the chromosomes and black arrows represent a rough phylogenetic tree of staphylococcal species based on 16S ribosome sequence. The distance between each species is not to the scale. Only the order of branching (speciation) from ancestral bacteria is shown. The relative locations and directions (synteny) of *pbp1-3* genes are well conserved among staphylococcal species. Note that synteny is incomplete with *pbp4* and *mecA*. They are located around the *oriC* (the *oriC* environ). In *S. carnosus*, two types of *pbp4* genes, denoted as *pbp4a* and *pbp4b*, are noticed [31].

the other, PBP4b to which *Micrococcus* PBP4 belongs (Fig. 7). Figure 8 shows the relative chromosomal locations and direction of transcription of the *pbp* genes on the macrococcal and staphylococcal chromosomes. The relative locations for *pbps1-3* are well conserved among *M. caseolyticus* and four staphylococcal species. The location of *pbp4a* relative to *pbps1-3* is conserved in several staphylococcal species. However, no *pbp4* is found in *S. epidermidis* strain RP62A, and *pbp4a* is absent but *pbp4b* is present in another *S. epidermidis* strain ATCC12228. Curiously, both *pbp4* subtypes are present in *S. haemolyticus* strain JCSC1435 and *S. carnosus* strain TM300. It is also remarkable that, like *mecA* gene, most of the *pbp4* genes are localized in the *oriC* environ (Fig. 8). The *pbp4b* of *S. epidermidis* strain ATCC12228 in Figure 8 was actually carried by an SCC element designated SCC*pbp4* [89]. Therefore, it is likely that at least a part of *pbp4* genes on staphylococcal species were acquired by horizontal gene transfer, whereas the set of three *pbps1-3* were vertically transmitted from the common ancestor of *macrococcal* and staphylococcal species.

In the case of *S. epidermidis* strains, vertically transmitted *pbp4a* might have been lost from RP62A by chromosome shuffling in the *oriC* environ, and ATCC12228 acquired *pbp4b* homolog as an SCC element by horizontal gene transfer. PBP4 is not essential for the viability of *S. aureus* [90], but its overproduction raises resistance to beta-lactam antibiotics [91]. By functioning as a transpeptidase, PBP4 increases peptidoglycan cross linkage, giving the cell wall a more rigid structure. Therefore, like *mecA*, *pbp4* seems to serve as a mobile *pbp* to aid  $\beta$ -lactam resistance of staphylococcal and related bacterial species.

### 9. Phenotypic expression of methicillin resistance

Acquisition and expression of *mecA* gene alone do not make the cell uniformly resistant to  $\beta$ -lactam antibiotics. The expression of MecA confers on the bacterial strain a moderate level of resistance to  $\beta$ -lactam antibiotics. The strain shows a unique pattern of antibiotic resistance called 'hetero-resistance'. Such MRSA is called hetero-MRSA. Figure 9 shows a typical  $\beta$ -lactam (methicillin)-resistance profile of a hetero-MRSA (strain N315 $\Delta$ IP) to which 64 mg/L of methicillin is effective to suppress the growth of 99.9% of N315 $\Delta$ IP (Fig. 9). However, the rest of the cell population does grow. The population is composed of heterogeneous subpopulations of cells with higher methicillin resistance in different degrees. Figure 9 shows that a minor subpopulation of N315 $\Delta$ IP consisting about one in 1 million part of the entire cell population can




grow even in the presence of 1,024 mg/L of methicillin (Fig. 9). Exposure of the hetero-MRSA strain to a potent  $\beta$ -lactam such as imipenem easily selects out a mutant strain, whose entire cell population is uniformly highly resistant to  $\beta$ -lactam antibiotics, called homogeneously methicillin-resistant *S. aureus* (homo-MRSA) [61, 92]. This change, designated 'hetero-to-homo conversion' of  $\beta$ -lactam resistance, is achieved by spontaneous mutations on the chromosome designated *chr\** [93].

So far mutations in *vraSR* (standing for vancomycin resistance sensor and response regulator) [94, 95], a two-component regulator system for *S. aureus* cell-wall synthesis, have been identified as *chr\**. Mutations *vraS* (H5N) and *vraS* (S329L) constitutively activate the regulatory system, and enhance cell-wall synthesis of the cell. Concomitant increase in resistance was observed against cell-wall synthesis inhibitor antibiotics such as  $\beta$ -lactam, fosfomycin, bacitracin, and glycopeptides [94].

## 10. Regulatory mutation for the expression of methicillin resistance

Now, extensive search for *chr\** can be done using high through-put whole genome sequencing strategy. By comparing




**Figure 9.** Four phenotype expressions of methicillin resistance.

Symbols: open circle, pre-MRSA strain N315 (*mecA* gene is only weakly induced in N315, because it is strongly repressed by the repressor protein encoded by an intact copy of *mecI* gene. Spontaneous mutational inactivation of *mecI* gene makes the cell express methicillin resistance by allowing constitutive production of the *mecA* gene transcript [48]); open square, hetero-MRSA strain N315 $\Delta$ IP (*mecI* gene-deletant of N315 expressing hetero-methicillin resistance); closed triangle, homo-MRSA strain N315 $\Delta$ IP-H5 (obtained by selecting N315 $\Delta$ IP with 8 mg/L of imipenem. Single mutation *rpoB*(N9671) is responsible for the 'hetero-to-homo conversion'); closed circle, strain N315*rpoB*(N9671) (the *chr\** mutation *rpoB*(N9671) was introduced into N315 by gene replacement procedure). Note that *chr\** causing hetero-to-homo conversion confers 'Eagle-phenotype' on the pre-MRSA [97].

the genome of hetero-MRSA strain  $\Delta$ IP and its derivative strain  $\Delta$ IP-H5, a mutant strain obtained by selection of  $\Delta$ IP with imipenem, we found a mutation *rpoB* (N9671) as a *chr\** for the hetero-to-homo conversion of MRSA [96]. Likewise, another mutation *rpoB* (R644H) was identified from a N315-derived strain N315h4 expressing 'Eagle-type' methicillin resistance [97]. Eagle type resistance has a unique population analysis curve as illustrated in Figure 9: more cells grow in the presence of higher concentrations of methicillin (32-256 mg/L) than in low concentrations (4 and 8 mg/L). Eagle-type resistance is known to be a special phenotypic expression of *chr\** in the 'pre-MRSA' strain N315 in which *mecA* gene expression is strongly repressed under the repressor function of *mecI* gene [48]. Since induction of *mecA* gene transcription by low concentrations of methicillin is weak and slow in pre-MRSA, cells die. The *rpoB* mutations seem to confer on the cell methicillin 'tolerance', and allow the cell survive in methicillin until enough amount of MecA is accumulated in the cell [48, 96].

*rpoB* gene encodes RNA polymerase  $\beta$  subunit RpoB. Mutation of *rpoB* has long been assigned significance only as the resistance marker for rifampin. Recently however, we started to notice that *rpoB* mutations affect various antibiotics other than rifampin (Fig. 10). One of the most frequent mutations *rpoB*(H481Y) raises not only rifampin resistance but also vancomycin-intermediate resistance of *S. aureus* [98]. Another mutation *rpoB* (Q468K) raises resistance to both rifampin and daptomycin. Mutations *rpoB* (T480M) and *rpoB* (R503H) do not affect rifampin susceptibility, and yet raise resistance to



**Figure 10.** *rpoB* gene mutation as the 'regulatory mutation'.

Those *rpoB* gene mutations found in-vitro-derived mutant strains and the phenotype of the strains are listed above the *rpoB* gene figure. Those in clinical strains that express altered susceptibilities to vancomycin,  $\beta$ -lactam, daptomycin and linezolid, but susceptible to rifampin ( $MIC_{RIF} < 1.0$  mg/L) are listed under the *rpoB* figure. The mutations in the clinical strains remain to be demonstrated for their direct contribution to the phenotypes.

teicoplanin, vancomycin, and daptomycin [98]. The two mutations *rpoB* (N967I) and *rpoB* (R644H) do not affect susceptibility to rifampin either, but cause hetero-to-homo conversion of methicillin resistance (Fig. 10) [96]. Curiously, practically all *rpoB* mutations so far identified conferred enhanced susceptibility to linezolid [98].

Depending on the locations of the mutations in *rpoB* gene and the kinds of amino acid substitutions the repertoire of affected antibiotics and the degrees of resistance are different [98]. Matsuo et al. showed that the resistant subpopulations of heterogeneously vancomycin-intermediate *S. aureus* (hVISA) contain the cells with many different *rpoB* mutations [98]. hVISA and hetero-MRSA share a similar population analysis curve. Therefore, it is likely that *rpoB* mutations are one of the major classes of mutations that determine the characteristic shape of the population curve of both hetero-MRSA and hVISA (Fig. 9).

*rpoB* mutations are well known to cause rifampin resistance by changing the conformation of the rifampin-binding site of RpoB. However, there are another class of *rpoB* mutations that decrease susceptibility to such antibiotics as glycopeptides,  $\beta$ -lactam, and daptomycin without affecting rifampin susceptibility. RpoB is not the target of these antibiotics. Therefore, those *rpoB* mutations are considered to change the antibiotic susceptibility of the cell indirectly by changing the physiology of the cell. In this sense, those *rpoB* mutations are regarded as 'regulatory mutations'. They confer changes in transcription profile of the cell by altering the interaction preferences of RNA polymerase holoenzyme for diverse transcription regulator proteins.

## Future perspective

Now, with a great technical advance in high thorough-put determination of nucleotide sequence, it became easy to determine and compare hundreds of bacterial genomes. By doing this, we will obtain a bird's view of the evolution of life on the earth. Antibiotic chemotherapy has long been faced with a difficult problem of antibiotic resistance. It is now evident that no antibiotic can escape the doom of emergence of resistance. As we have seen, however, methicillin resistance is likely to have existed long before the advent of mammals in the history of life. We may reasonably think that antibiotic resistance is not an outcome of human misconduct. Apparent vicious cycle of antibiotic and antibiotic resistance may be regarded as a providence of nature. We recently found a curious class of

antibiotic designated Reverse Antibiotic (RA), which was active against quinolone-resistant *S. aureus* but inactive against quinolone-susceptible *S. aureus* [99]. RA was found in the soil of earth as a natural product. It is futile to try to disrupt the vicious cycle by incessantly producing new antibiotics. Instead, we may learn how to control the procession of the vicious cycle by closely observing the life history of earth, where all the opponent microorganisms seem to coexist in a dynamic equilibrium.

## Acknowledgement

We thank Dr Ikuo Uchiyama for his help in the computer analysis of orthologous *orfs* conserved across bacterial species. This study was supported by Grant-in-Aid for (S1201013) from MEXT (Ministry of Education, Culture, Sports, Science and Technology) - Supported Program for the Strategic Research Foundation at Private Universities, 2012 - 2017.

## References

1. Hiramatsu K. Molecular evolution of MRSA. *Microbiol Immunol* 1995;39:531-43.
2. Jevons MP. 'Celbenin'-resistant staphylococci. *BMJ* 1961;1:124-5.
3. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). *Proc Natl Acad Sci U S A* 2002;99:7687-92.
4. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *J Antimicrob Chemother* 1997;40:135-6.
5. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK; Vancomycin-Resistant *Staphylococcus aureus* Investigative Team. Infection with vancomycin-resistant *Staphylococcus aureus* containing the *vanA* resistance gene. *N Engl J Med* 2003;348:1342-7.
6. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant *Staphylococcus aureus* in Western Australia. *J Hosp Infect* 1993;25:97-108.
7. Riley TV, Pearman JW, Rouse IL. Changing epidemiology of methicillin-resistant *Staphylococcus aureus* in Western

- Australia. *Med J Aust* 1995;163:412-4.
8. Moreno F, Crisp C, Jorgensen JH, Patterson JE. Methicillin-resistant *Staphylococcus aureus* as a community organism. *Clin Infect Dis* 1995;21:1308-12.
  9. Aubry-Damon H, Legrand P, Brun-Buisson C, Astier A, Soussy CJ, Leclercq R. Reemergence of gentamicin-susceptible strains of methicillin-resistant *Staphylococcus aureus*: roles of an infection control program and changes in aminoglycoside use. *Clin Infect Dis* 1997;25:647-53.
  10. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, Kuroda H, Cui L, Yamamoto K, Hiramatsu K. Genome and virulence determinants of high virulence community-acquired MRSA. *Lancet* 2002;359:1819-27.
  11. Takeuchi F, Watanabe S, Baba T, Yuzawa H, Ito T, Morimoto Y, Kuroda M, Cui L, Takahashi M, Ankai A, Baba S, Fukui S, Lee JC, Hiramatsu K. Whole-genome sequencing of *Staphylococcus haemolyticus* uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species. *J Bacteriol* 2005;187:7292-308.
  12. Lindsay JA, Ruzin A, Ross HF, Kurepina N, Novick RP. The gene for toxic shock toxin is carried by a family of mobile pathogenicity islands in *Staphylococcus aureus*. *Mol Microbiol* 1998;29:527-43.
  13. Novick RP, Subedi A. The SaPIs: mobile pathogenicity islands of *Staphylococcus*. *Chem Immunol Allergy* 2007;93:42-57.
  14. O'Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of *Staphylococcus aureus*. *J Clin Microbiol* 2007;45:1505-10.
  15. Ubeda C, Maiques E, Tormo MA, Campoy S, Lasa I, Barbé J, Novick RP, Penadés JR. SaPI operon I is required for SaPI packaging and is controlled by LexA. *Mol Microbiol* 2007;65:41-50.
  16. Tormo MA, Ferrer MD, Maiques E, Ubeda C, Selva L, Lasa I, Calvete JJ, Novick RP, Penadés JR. *Staphylococcus aureus* pathogenicity island DNA is packaged in particles composed of phage proteins. *J Bacteriol* 2008;190:2434-40.
  17. Chen J, Novick RP. Phage-mediated intergeneric transfer of toxin genes. *Science* 2009;323:139-41.
  18. Baba T, Kuwahara-Arai K, Uchiyama I, Takeuchi F, Ito T, Hiramatsu K. Complete genome sequence determination of a *Macrococcus caseolyticus* strain JSCS5402 reflecting the ancestral genome of the human pathogenic staphylococci. *J Bacteriol* 2009;191:1180-90.
  19. Gill SR, Fouts DE, Archer GL, Mongodin EF, Deboy RT, Ravel J, Paulsen IT, Kolonay JF, Brinkac L, Beanan M, Dodson RJ, Daugherty SC, Madupu R, Angiuoli SV, Durkin AS, Haft DH, Vamathevan J, Khouri H, Utterback T, Lee C, Dimitrov G, Jiang L, Qin H, Weidman J, Tran K, Kang K, Hance IR, Nelson KE, Fraser CM. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant *Staphylococcus aureus* strain and a biofilm-producing methicillin-resistant *Staphylococcus epidermidis* strain. *J Bacteriol* 2005;187:2426-38.
  20. Lina G, Bohach GA, Nair SP, Hiramatsu K, Jouvin-Marche E, Mariuzza R; International Nomenclature Committee for Staphylococcal Superantigens. Standard nomenclature for the superantigens expressed by *Staphylococcus*. *J Infect Dis* 2004;189:2334-6.
  21. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. *J Immunol* 2005;174:2926-33.
  22. Baba T, Takeuchi F, Kuroda M, Ito T, Yuzawa H, Hiramatsu K. The *Staphylococcus aureus* genome. In: Ala'Aldeen D, Hiramatsu K, eds. *Staphylococcus aureus* Molecular and Clinical Aspects. Chichester, UK: Horwood Publishing; 2004:66-153.
  23. Yamaguchi T, Nishifuji K, Sasaki M, Fudaba Y, Aepfelbacher M, Takata T, Ohara M, Komatsuzawa H, Amagai M, Sugai M. Identification of the *Staphylococcus aureus* etd pathogenicity island which encodes a novel exfoliative toxin, ETD, and EDIN-B. *Infect Immun* 2002;70:5835-45.
  24. Manna AC, Cheung AL. *sarU*, a *sarA* homolog, is repressed by SarT and regulates virulence genes in *Staphylococcus aureus*. *Infect Immun* 2003;71:343-53.
  25. Jamaluddin TZ, Kuwahara-Arai K, Hisata K, Terasawa M, Cui L, Baba T, Sotozono C, Kinoshita S, Ito T, Hiramatsu K. Extreme genetic diversity of methicillin-resistant *Staphylococcus epidermidis* strains disseminated among healthy Japanese children. *J Clin Microbiol* 2008;46:3778-83.
  26. Watanabe S, Ito T, Morimoto Y, Takeuchi F, Hiramatsu K. Precise excision and self-integration of a composite transposon as a model for spontaneous large-scale chromosome inversion/deletion of the *Staphylococcus haemolyticus* clinical strain JCSC1435. *J Bacteriol* 2007;189:2921-5.
  27. Gustafson J, Strässle A, Hächler H, Kayser FH, Berger-Bächi B. The *femC* locus of *Staphylococcus aureus* required for methicillin resistance includes the glutamine synthetase operon. *J Bacteriol* 1994;176:1460-7.

28. Maki H, Murakami K. Formation of potent hybrid promoters of the mutant *ilm* gene by IS256 transposition in methicillin-resistant *Staphylococcus aureus*. *J Bacteriol* 1997;179:6944-8.
29. Hiramatsu K. Vancomycin resistance in staphylococci. *Drug Resist Updat* 1998;1:135-50.
30. Kozitskaya S, Cho SH, Dietrich K, Marre R, Naber K, Ziebuhr W. The bacterial insertion sequence element IS256 occurs preferentially in nosocomial *Staphylococcus epidermidis* isolates: association with biofilm formation and resistance to aminoglycosides. *Infect Immun* 2004;72:1210-5.
31. Rosenstein R, Nerz C, Biswas L, Resch A, Raddatz G, Schuster SC, Götz F. Genome analysis of the meat starter culture bacterium *Staphylococcus carnosus* TM300. *Appl Environ Microbiol* 2009;75:811-22.
32. Ito T, Katayama Y, Hiramatsu K. Cloning and nucleotide sequence determination of the entire *mec* DNA of pre-methicillin-resistant *Staphylococcus aureus* N315. *Antimicrob Agents Chemother* 1999;43:1449-58.
33. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome *mec*, encodes methicillin resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2000;44:1549-55.
34. Sjöström JE, Löfdahl S, Philipson L. Transformation reveals a chromosomal locus of the gene(s) for methicillin resistance in *Staphylococcus aureus*. *J Bacteriol* 1975;123:905-15.
35. Kuhl SA, Pattee PA, Baldwin JN. Chromosomal map location of the methicillin resistance determinant in *Staphylococcus aureus*. *J Bacteriol* 1978;135:460-5.
36. Stewart GC, Rosenblum ED. Genetic behavior of the methicillin resistance determinant in *Staphylococcus aureus*. *J Bacteriol* 1980;144:1200-2.
37. Brown DF, Reynolds PE. Intrinsic resistance to beta-lactam antibiotics in *Staphylococcus aureus*. *FEBS Lett* 1980;122:275-8.
38. Hartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in *Staphylococcus aureus*. *J Bacteriol* 1984;158:513-6.
39. Utsui Y, Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1985;28:397-403.
40. Ubukata K, Yamashita N, Konno M. Occurrence of a beta-lactam-inducible penicillin-binding protein in methicillin-resistant staphylococci. *Antimicrob Agents Chemother* 1985;27:851-7.
41. Matsuhashi M, Song MD, Ishino F, Wachi M, Doi M, Inoue M, Ubukata K, Yamashita N, Konno M. Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in *Staphylococcus aureus*. *J Bacteriol* 1986;167:975-80.
42. Song MD, Wachi M, Doi M, Ishino F, Matsuhashi M. Evolution of an inducible penicillin-target protein in methicillin-resistant *Staphylococcus aureus* by gene fusion. *FEBS Lett* 1987;221:167-71.
43. Tesch W, Ryffel C, Strässle A, Kayser FH, Berger-Bächi B. Evidence of a novel staphylococcal *mec*-encoded element (*mecR*) controlling expression of penicillin-binding protein 2'. *Antimicrob Agents Chemother* 1990;34:1703-6.
44. Hürlimann-Dalel RL, Ryffel C, Kayser FH, Berger-Bächi B. Survey of the methicillin resistance-associated genes *mecA*, *mecR1-mecI*, and *femA-femB* in clinical isolates of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1992;36:2617-21.
45. Suzuki E, Kuwahara-Arai K, Richardson JE, Hiramatsu K. Distribution of *mec* regulator genes in methicillin-resistant *Staphylococcus* clinical strains. *Antimicrob Agents Chemother* 1993;37:1219-26.
46. Ryffel C, Kayser FH, Berger-Bächi B. Correlation between regulation of *mecA* transcription and expression of methicillin resistance in staphylococci. *Antimicrob Agents Chemother* 1992;36:25-31.
47. Hiramatsu K, Asada K, Suzuki E, Okonogi K, Yokota T. Molecular cloning and nucleotide sequence determination of the regulator region of *mecA* gene in methicillin-resistant *Staphylococcus aureus* (MRSA). *FEBS Lett* 1992;298:133-6.
48. Kuwahara-Arai K, Kondo N, Hori S, Tateda-Suzuki E, Hiramatsu K. Suppression of methicillin resistance in a *mecA*-containing pre-methicillin-resistant *Staphylococcus aureus* strain is caused by the *mecI*-mediated repression of PBP 2' production. *Antimicrob Agents Chemother* 1996;40:2680-5.
49. Ito T, Katayama Y, Asada K, Mori N, Tsutsumimoto K, Tiensasitorn C, Hiramatsu K. Structural comparison of three types of staphylococcal cassette chromosome *mec* integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2001;45:1323-36.
50. Hiramatsu K, Kondo N, Ito T. Genetic basis for molecular epidemiology of MRSA. *J Infect Chemother* 1996;2:117-29.
51. Stokes HW, Hall RM. A novel family of potentially mobile DNA elements encoding site-specific gene-integration



- functions: integrons. *Mol Microbiol* 1989;3:1669-83.
52. Hiramatsu K, Katayama Y, Yuzawa H, Ito T. Molecular genetics of methicillin-resistant *Staphylococcus aureus*. *Int J Med Microbiol* 2002;292:67-74.
  53. Chongtrakool P, Ito T, Ma XX, Kondo Y, Trakulsomboon S, Tiensasitorn C, Jamklang M, Chavalit T, Song JH, Hiramatsu K. Staphylococcal cassette chromosome *mec* (SCC*mec*) typing of methicillin-resistant *Staphylococcus aureus* strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCC*mec* elements. *Antimicrob Agents Chemother* 2006;50:1001-12.
  54. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, Hiramatsu K. Combination of multiplex PCRs for staphylococcal cassette chromosome *mec* type assignment: rapid identification system for *mec*, *ccr*, and major differences in junkyard regions. *Antimicrob Agents Chemother* 2007;51:264-74.
  55. Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S, Daum RS, Hiramatsu K. Novel type of staphylococcal cassette chromosome *mec* identified in community-acquired methicillin-resistant *Staphylococcus aureus* strains. *Antimicrob Agents Chemother* 2002;46:1147-52.
  56. Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel type V staphylococcal cassette chromosome *mec* driven by a novel cassette chromosome recombinase, *ccrC*. *Antimicrob Agents Chemother* 2004;48:2637-51.
  57. International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC). Classification of staphylococcal cassette chromosome *mec* (SCC*mec*): guidelines for reporting novel SCC*mec* elements. *Antimicrob Agents Chemother* 2009;53:4961-7.
  58. Okuma K, Iwakawa K, Turnidge JD, Grubb WB, Bell JM, O'Brien FG, Coombs GW, Pearman JW, Tenover FC, Kapi M, Tiensasitorn C, Ito T, Hiramatsu K. Dissemination of new methicillin-resistant *Staphylococcus aureus* clones in the community. *J Clin Microbiol* 2002;40:4289-94.
  59. Hisata K, Kuwahara-Arai K, Yamanoto M, Ito T, Nakatomi Y, Cui L, Baba T, Terasawa M, Sotozono C, Kinoshita S, Yamashiro Y, Hiramatsu K. Dissemination of methicillin-resistant staphylococci among healthy Japanese children. *J Clin Microbiol* 2005;43:3364-72.
  60. Ruppé E, Barbier F, Mesli Y, Maiga A, Cojocar R, Benkhalafat M, Benchouk S, Hassaine H, Maiga I, Diallo A, Koumaré AK, Ouattara K, Soumaré S, Dufourcq JB, Nareth C, Sarthou JL, Andreumont A, Ruimy R. Diversity of staphylococcal cassette chromosome *mec* structures in methicillin-resistant *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* strains among outpatients from four countries. *Antimicrob Agents Chemother* 2009;53:442-9.
  61. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol* 2001;9:486-93.
  62. Chambers HF. The changing epidemiology of *Staphylococcus aureus*? *Emerg Infect Dis* 2001;7:178-82.
  63. Zhang HZ, Hackbarth CJ, Chansky KM, Chambers HF. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. *Science* 2001;291:1962-5.
  64. Hiramatsu K, Suzuki E, Takayama H, Katayama Y, Yokota T. Role of penicillinase plasmids in the stability of the *mecA* gene in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1990;34:600-4.
  65. Wada A, Katayama Y, Hiramatsu K, Yokota T. Southern hybridization analysis of the *mecA* deletion from methicillin-resistant *Staphylococcus aureus*. *Biochem Biophys Res Commun* 1991;176:1319-25.
  66. Lee SM, Ender M, Adhikari R, Smith JM, Berger-Bächi B, Cook GM. Fitness cost of staphylococcal cassette chromosome *mec* in methicillin-resistant *Staphylococcus aureus* by way of continuous culture. *Antimicrob Agents Chemother* 2007;51:1497-9.
  67. Chatterjee SS, Chen L, Joo HS, Cheung GY, Kreiswirth BN, Otto M. Distribution and regulation of the mobile genetic element-encoded phenol-soluble modulins PSM-*mec* in methicillin-resistant *Staphylococcus aureus*. *PLoS One* 2011;6:e28781.
  68. Kaito C, Sekimizu K. Colony spreading in *Staphylococcus aureus*. *J Bacteriol* 2007;189:2553-7.
  69. Kaito C, Omae Y, Matsumoto Y, Nagata M, Yamaguchi H, Aoto T, Ito T, Hiramatsu K, Sekimizu K. A novel gene, *fu-doh*, in the SCC*mec* region suppresses the colony spreading ability and virulence of *Staphylococcus aureus*. *PLoS ONE* 2008;3:e3921.
  70. Hongo I, Baba T, Oishi K, Morimoto Y, Ito T, Hiramatsu K. Phenol-soluble modulins alpha 3 enhances the human neutrophil lysis mediated by Pantone-Valentine leukocidin. *J Infect Dis* 2009;200:715-23.
  71. Kaito C, Saito Y, Nagano G, Ikuo M, Omae Y, Hanada Y, Han X, Kuwahara-Arai K, Hishinuma T, Baba T, Ito T, Hiramatsu K, Sekimizu K. Transcription and translation products of the cytolysin gene *psm-mec* on the mobile genetic element SCC*mec* regulate *Staphylococcus aureus* virulence. *PLoS Pathog* 2011;7:e1001267.

72. Kaito C, Saito Y, Ikuo M, Omae Y, Mao H, Nagano G, Fujiyuki T, Numata S, Han X, Obata K, Hasegawa S, Yamaguchi H, Inokuchi K, Ito T, Hiramatsu K, Sekimizu K. Mobile genetic element SCC*mec*-encoded *psm-mec* RNA suppresses translation of *agrA* and attenuates MRSA virulence. *PLoS Pathog* 2013;9: e1003269.
73. Luong TT, Ouyang S, Bush K, Lee CY. Type 1 capsule genes of *Staphylococcus aureus* are carried in a staphylococcal cassette chromosome genetic element. *J Bacteriol* 2002;184:3623-9.
74. Holden MT, Feil EJ, Lindsay JA, Peacock SJ, Day NP, Enright MC, Foster TJ, Moore CE, Hurst L, Atkin R, Barron A, Bason N, Bentley SD, Chillingworth C, Chillingworth T, Churcher C, Clark L, Corton C, Cronin A, Doggett J, Dowd L, Feltwell T, Hance Z, Harris B, Hauser H, Holroyd S, Jagels K, James KD, Lennard N, Line A, Mayes R, Moule S, Mungall K, Ormond D, Quail MA, Rabinowitsch E, Rutherford K, Sanders M, Sharp S, Simmonds M, Stevens K, Whitehead S, Barrell BG, Spratt BG, Parkhill J. Complete genomes of two clinical *Staphylococcus aureus* strains: evidence for the rapid evolution of virulence and drug resistance. *Proc Natl Acad Sci U S A* 2004;101:9786-91.
75. Zhang YQ, Ren SX, Li HL, Wang YX, Fu G, Yang J, Qin ZQ, Miao YG, Wang WY, Chen RS, Shen Y, Chen Z, Yuan ZH, Zhao GP, Qu D, Danchin A, Wen YM. Genome-based analysis of virulence genes in a non-biofilm-forming *Staphylococcus epidermidis* strain (ATCC 12228). *Mol Microbiol* 2003;49:1577-93.
76. Diep BA, Gill SR, Chang RE, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, Sensabaugh GF, Perdreau-Remington F. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant *Staphylococcus aureus*. *Lancet* 2006;367:731-9.
77. Wu S, Piscitelli C, de Lencastre H, Tomasz A. Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of *mecA* from a methicillin susceptible strain of *Staphylococcus sciuri*. *Microb Drug Resist* 1996;2:435-41.
78. Tsubakishita S, Kuwahara-Arai K, Sasaki T, Hiramatsu K. Origin and molecular evolution of the determinant of methicillin resistance in staphylococci. *Antimicrob Agents Chemother* 2010;54:4352-9.
79. Hiramatsu K, Tsubakishita S, Matsuo M, Sasaki T. Molecular Evolution of MRSA 2010. 12th Western Pacific Congress on Chemotherapy and Infectious Diseases: 2011 Dec 2-5; Singapore. p.11-8.
80. Tsubakishita S, Kuwahara-Arai K, Baba T, Hiramatsu K. Staphylococcal cassette chromosome *mec*-like element in *Macrococcus caseolyticus*. *Antimicrob Agents Chemother* 2010;54:1469-75.
81. García-Álvarez L, Holden MT, Lindsay H, Webb CR, Brown DF, Curran MD, Walpole E, Brooks K, Pickard DJ, Teale C, Parkhill J, Bentley SD, Edwards GF, Girvan EK, Kearns AM, Pichon B, Hill RL, Larsen AR, Skov RL, Peacock SJ, Maskell DJ, Holmes MA. Methicillin-resistant *Staphylococcus aureus* with a novel *mecA* homologue in human and bovine populations in the UK and Denmark: a descriptive study. *Lancet Infect Dis* 2011;11:595-603.
82. Shore AC, Deasy EC, Slickers P, Brennan G, O'Connell B, Monecke S, Ehrlich R, Coleman DC. Detection of staphylococcal cassette chromosome *mec* type XI carrying highly divergent *mecA*, *mecI*, *mecR1*, *blaZ*, and *ccr* genes in human clinical isolates of clonal complex 130 methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2011;55:3765-73.
83. Harrison EM, Paterson GK, Holden MT, Morgan FJ, Larsen AR, Petersen A, Leroy S, De Vlieghe S, Perreten V, Fox LK, Lam TJ, Sampimon OC, Zadoks RN, Peacock SJ, Parkhill J, Holmes MA. A *Staphylococcus xylosus* isolate with a new *mecC* allotype. *Antimicrob Agents Chemother* 2013;57:1524-8.
84. Schnellmann C, Gerber V, Rossano A, Jaquier V, Panchaud Y, Doherr MG, Thomann A, Straub R, Perreten V. Presence of new *mecA* and *mph(C)* variants conferring antibiotic resistance in *Staphylococcus* spp. isolated from the skin of horses before and after clinic admission. *J Clin Microbiol* 2006;44:4444-54.
85. Fontana R, Ligozzi M, Pittaluga F, Satta G. Intrinsic penicillin resistance in enterococci. *Microb Drug Resist* 1996;2:209-13.
86. Williamson R, le Bouguéne C, Gutmann L, Horaud T. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of *Enterococcus faecium* to benzylpenicillin. *J Gen Microbiol* 1985;131:1933-40.
87. el Kharroubi A, Jacques P, Piras G, Van Beeumen J, Coyette J, Ghuysen JM. The *Enterococcus hirae* R40 penicillin-binding protein 5 and the methicillin-resistant *Staphylococcus aureus* penicillin-binding protein 2' are similar. *Biochem J* 1991;280:463-9.
88. Piras G, Raze D, el Kharroubi A, Hastir D, Englebort S, Coyette J, Ghuysen JM. Cloning and sequencing of the low-affinity penicillin-binding protein 3r-encoding gene

- of *Enterococcus hirae* S185: modular design and structural organization of the protein. *J Bacteriol* 1993;175:2844-52.
89. Mongkolrattanothai K, Boyle S, Murphy TV, Daum RS. Novel non-mecA-containing staphylococcal chromosomal cassette composite island containing *pbp4* and *tagF* genes in a commensal staphylococcal species: a possible reservoir for antibiotic resistance islands in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2004;48:1823-36.
90. Wyke AW, Ward JB, Hayes MV, Curtis NA. A role *in vivo* for penicillin-binding protein-4 of *Staphylococcus aureus*. *Eur J Biochem* 1981;119:389-93.
91. Henze UU, Roos M, Berger-Bächi B. Effects of penicillin-binding protein 4 overproduction in *Staphylococcus aureus*. *Microb Drug Resist* 1996;2:193-9.
92. Yamakawa J, Aminaka M, Okuzumi K, Kobayashi H, Katayama Y, Kondo S, Nakamura A, Oguri T, Hori S, Cui L, Ito T, Jin J, Kurosawa H, Kaneko K, Hiramatsu K. Heterogeneously vancomycin-intermediate *Staphylococcus aureus* (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study. *J Infect Chemother* 2012;18:406-9.
93. Ryffel C, Strässle A, Kayser FH, Berger-Bächi B. Mechanisms of heteroresistance in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1994;38:724-8.
94. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. Two-component system *VraSR* positively modulates the regulation of cell-wall biosynthesis pathway in *Staphylococcus aureus*. *Mol Microbiol* 2003;49:807-21.
95. Kuroda M, Kuwahara-Arai K, Hiramatsu K. Identification of the up- and down-regulated genes in vancomycin-resistant *Staphylococcus aureus* strains Mu3 and Mu50 by cDNA differential hybridization method. *Biochem Biophys Res Commun* 2000;269:485-90.
96. Aiba Y, Katayama Y, Hishinuma T, Murakami-Kuroda H, Cui L, Hiramatsu K. Mutation of RNA polymerase  $\beta$ -subunit gene promotes hetero-to-homo conversion of  $\beta$ -lactam resistance of methicillin-resistant *Staphylococcus aureus*. [Submitted].
97. Kondo N, Kuwahara-Arai K, Kuroda-Murakami H, Tateda-Suzuki E, Hiramatsu K. Eagle-type methicillin resistance: new phenotype of high methicillin resistance under *mec* regulator gene control. *Antimicrob Agents Chemother* 2001;45:815-24.
98. Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K. Mutation of RNA polymerase beta subunit (*rpoB*) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. *Antimicrob Agents Chemother* 2011;55:4188-95.
99. Hiramatsu K, Igarashi M, Morimoto Y, Baba T, Umekita M, Akamatsu Y. Curing bacteria of antibiotic resistance: reverse antibiotics, a novel class of antibiotics in nature. *Int J Antimicrob Agents* 2012;39:478-85.
100. Uchiyama I. MGD: a platform for microbial comparative genomics based on the automated construction of orthologous groups. *Nucleic Acids Res* 2007;35:D343-6.
101. Uchiyama I. Hierarchical clustering algorithm for comprehensive orthologous-domain classification in multiple genomes. *Nucleic Acids Res* 2006;34:647-58.
102. Clarke SR, Harris LG, Richards RG, Foster SJ. Analysis of *Ebh*, a 1.1-megadalton cell wall-associated fibronectin-binding protein of *Staphylococcus aureus*. *Infect Immun* 2002;70:6680-7.
103. Herron-Olson L, Fitzgerald JR, Musser JM, Kapur V. Molecular correlates of host specialization in *Staphylococcus aureus*. *PLoS One* 2007;2:e1120.
104. Uchiyama I. Multiple genome alignment for identifying the core structure among moderately related microbial genomes. *BMC Genomics* 2008;9:515.
105. Yarwood JM, McCormick JK, Paustian ML, Orwin PM, Kapur V, Schlievert PM. Characterization and expression analysis of *Staphylococcus aureus* pathogenicity island 3. Implications for the evolution of staphylococcal pathogenicity islands. *J Biol Chem* 2002;277:13138-47.
106. Highlander SK, Hultén KG, Qin X, Jiang H, Yerrapragada S, Mason EO Jr, Shang Y, Williams TM, Fortunov RM, Liu Y, Igboeli O, Petrosino J, Tirumalai M, Uzman A, Fox GE, Cardenas AM, Muzny DM, Hemphill L, Ding Y, Dugan S, Blyth PR, Buhay CJ, Dinh HH, Hawes AC, Holder M, Kovar CL, Lee SL, Liu W, Nazareth LV, Wang Q, Zhou J, Kaplan SL, Weinstock GM. Subtle genetic changes enhance virulence of methicillin resistant and sensitive *Staphylococcus aureus*. *BMC Microbiol* 2007;7:99.
107. Fitzgerald JR, Monday SR, Foster TJ, Bohach GA, Hartigan PJ, Meaney WJ, Smyth CJ. Characterization of a putative pathogenicity island from bovine *Staphylococcus aureus* encoding multiple superantigens. *J Bacteriol* 2001;183:63-70.
108. Ubeda C, Tormo MA, Cucarella C, Trottonda P, Foster TJ, Lasa I, Penadés JR. *Sip*, an integrase protein with excision, circularization and integration activities, defines a new family of mobile *Staphylococcus aureus* pathogenicity islands. *Mol Microbiol* 2003;49:193-210.

109. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K. Whole genome sequencing of methicillin-resistant *Staphylococcus aureus*. *Lancet* 2001;357:1225-40.
110. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. Genome sequence of *Staphylococcus aureus* strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. *J Bacteriol* 2008;190:300-10.
111. Subedi A, Ubeda C, Adhikari RP, Penadés JR, Novick RP. Sequence analysis reveals genetic exchanges and intraspecific spread of SaPI2, a pathogenicity island involved in menstrual toxic shock. *Microbiology* 2007;153:3235-45.
112. Kwan T, Liu J, DuBow M, Gros P, Pelletier J. The complete genomes and proteomes of 27 *Staphylococcus aureus* bacteriophages. *Proc Natl Acad Sci U S A* 2005;102:5174-9.